PHARMACEUTICAL PREPARATIONS
Vyome Holdings, Inc. Common Stock
HIND
Vyome Holdings Inc is a clinical-stage specialty pharmaceutical company working to treat immune-inflammatory and rare diseases of unmet need with next-generation therapeutic solutions. Its product candidates are: VT-1953, a topical gel that is being developed to treat signs and symptoms of malignant fungating wounds in cancer; VT-1908, a repurposed immune modulator to treat steroid-sparing anterior uveitis; and VB1953, which is being developed to treat moderate to severe acne. Vyome has also commercialized two novel reformulated topical anti-fungal products based on the technology platform of Molecular Replacement Therapeutics (MRT) in India: a dandruff lotion and shampoo. It operates in two segments: pharmaceutical products, which generate the maximum revenue, and biotechnology.
Open XNAS
Fundamentals
Key company ratios and reported financial statements.
Key ratios
Valuation
- Market capitalization
- $10.74M
- Price / earnings
- —
- Price / book
- 2.02×
- Price / sales
- 70.14×
- EV / sales
- 24.7×
- EV / EBITDA
- -0.87×
Profitability
- Earnings per share
- -$0.58
- Return on assets
- -47.18%
- Return on equity
- -76.26%
- Dividend yield
- 0%
Liquidity and leverage
- Debt / equity
- 0×
- Current ratio
- 3.68×
- Quick ratio
- 3.68×
- Cash ratio
- 3.37×
Cash flow
- Price / cash flow
- —
- Price / free cash flow
- —
- Free cash flow
- -$4.45M
Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.
| Line item | Q3 FY2026 Sep 30, 2026 | Q2 FY2026 Jun 30, 2026 | Q1 FY2026 Mar 31, 2026 | Q4 FY2025 Dec 31, 2025 | Q3 FY2025 Sep 30, 2025 |
|---|---|---|---|---|---|
| Revenue | $58K | $26.96K | $31.59K | $36.55K | $34.63K |
| Cost of revenue | $31.2K | $15.3K | $14.95K | $14.49K | $16.58K |
| Gross profit | $26.8K | $11.66K | $16.65K | $22.07K | $18.05K |
| Selling, general and administrative | $635.41K | $364.89K | $477.58K | $996.2K | $844.34K |
| Research and development | $409.83K | $506.72K | $666.41K | $378.25K | $39.68K |
| Total operating expenses | $1.05M | $874.22K | $1.15M | $1.38M | $8.59M |
| Operating income | -$1.02M | -$862.57K | -$1.13M | -$1.36M | -$8.57M |
| Interest expense | -$2.94K | -$3.33K | -$2.85K | -$9.94K | -$25.6K |
| Income before taxes | -$930.33K | -$719.68K | -$985.52K | -$1.28M | -$8.6M |
| Income taxes | $0 | $0 | $0 | $0 | $0 |
| Net income | -$930.33K | -$719.68K | -$985.52K | -$1.28M | -$8.6M |
| Net income attributable to common shareholders | -$885.41K | -$685.56K | -$1.02M | -$1.47M | -$8.43M |
| EBITDA | -$1.02M | -$859.96K | -$1.13M | -$1.35M | -$8.57M |
| Basic earnings per share | -$0.13 | -$0.10 | -$0.15 | -$0.25 | -$3.06 |
| Diluted earnings per share | -$0.13 | -$0.10 | -$0.15 | -$0.25 | -$3.06 |
Recent news
Company coverage with links to the original publishers.
No recent company news found.
Dividends
Declared distributions and recorded event dates. Forecasts are not shown.
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.
| Execution date | Split ratio | Event type |
|---|---|---|
| Aug 15, 2025 | 1-for-4 | reverse split |